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Abstract Cultured neonatal rat ventricular myocytes were co-transfected with expression plasmids encoding protein kinase C (PKC) isoforrns from 
each of the PKC subfamilies (classical PKC-a, novel PKC-.e or atypical PKC-0 together with an atria1 natriuretic factor (ANF) reporter plasmid. 
Each PKC had been rendered constitutively active by a single Ala+Glu mutation or a small deletion in the inhibitory pseudosubstrate site. cPKC-a, 
nPKC-& or aPKC-c expression plasmids each stimulated ANF-promoter activity and expression of a reporter gene under the control of a 12-0- 
tetradecanoylphorbol 13-acetate-response el ment (TRE). Upregulation of the ANF promoter is characteristic of the hypertrophic response in the 
heart ventricle and a TRE is present in the ANF promoter. Thus all subfamilies of PKC may have the potential to contribute to hypertrophic response 
in cardiomyocytes. 
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1. Introduction 
Postnatally, cardiac myocytes become amitotic and respond 
to a variety of trophic signals in vivo by increasing their size 
and myofibrillar content. Similarly, ventricular myocytes in 
culture display increased organisation of contractile proteins 
into sarcomeres and distinct changes in gene expression (re- 
viewed in [ 11). The latter includes rapid induction of immediate 
early genes such as c-fos, c-jun and Egr- 1, re-expression of genes 
normally only expressed during foetal ventricular development 
(ANF, B-MHC, skeletal muscle cz-actin) and the up-regulation 
of constitutively-expressed contractile protein genes such as 
ventricular MLC-2 and cardiac muscle a-actin. 
The molecular mechanisms underlying these changes are still 
poorly understood, though participation of PKC is implicated. 
Many hypertrophic agonists activate PKC in cardiomyocytes 
[2-71. TPA increases myocyte size, protein synthesis and pro- 
motes the changes in gene expression associated with the hy- 
pertrophic response [S-12]. Transfection of cardiomyocytes 
with plasmids in which PKC-a or PKC-fi rendered constitu- 
tively-active by large N-terminal deletions induces up-regula- 
tion of co-transfected j?-MHC [13], ANF- [3] or MLC-Zre- 
porter [3] genes. However, these deletions remove structure 
(reviewed in [14]) involved in PKC regulation (substrate selec- 
tion, subcellular localisation, etc.). 
Although this evidence supports a role for PKC in the hy- 
pertrophic response, whether there is any specificity in terms 
of PKC isoform involvement has never been ascertained. PKC 
is a family of at least twelve phospholipid-dependent Ser-/Thr- 
*Corresponding author. Fax: (44) (71) 823-3392. 
Abbreviations: ANF, atria1 natriuretic factor; AP-1, activator protein-l; 
/?-Gal, B-galactosidase; CMV, cytomegalovirus; LUX, luciferase; 
&MHC, /I-myosin heavy chain; MLC, myosin light chain; PBS, phos- 
phate-buffered saline; PKC, protein kinase C; t@S, pseudosubstrate 
site; &SS, ySS deletion; TPA, 12-0-tetradecanoylphorbol 13-acetate; 
TRE, TPA response element; wt, wild type. 
protein kinases (reviewed in [14-161) which can divided into the 
following subfamilies: (i) classical (cPKC-a, -j?,, -p2 and -y) 
which require both Ca” and diacylglycerol (or phorbol esters 
such as TPA) for activity; (ii) novel (nPKC-6, -E, -r,r, -0 and -p) 
which have lost the requirement for Ca”; and (iii) atypical 
(aPKC-c, -I and -2) which are Ca”-independent and are not 
activated by diacylglycerol. Using isoform-specific antisera, we 
and others have shown that cPKC-a, nPKC-6, nPKC-.s and 
aPKC-c are present in cultured neonatal rat cardiomyocytes 
t5,6,171. 
The present work had two aims. First, to determine whether 
expression of PKC isoforms rendered constitutively-active by 
single amino acid mutations or small deletions in the vSS (as 
opposed to large N-terminal deletions) induce the expression 
of a marker gene (ANF) for the hypertrophic response in car- 
diomyocytes. Secondly, whether a specific PKC subfamily stim- 
ulates its expression. 
2. Experimental 
2.1. Plasmid constructs 
For each PKC isoform studied, expression vectors harbourecl: 
(i) wild type PKC; (ii) PKC with a @?.S (A+E) mutation producing 
a constitutively-active (A,,-+E in cPKC-a [18], A,,,+E in nPKC-.z 
[ 191, A, ,9 + E in aPKCC [20]; (iii) PKC with a &SS of residues 22-28 
in cPKC-cc [18], residues 154163 in nPKC-& [19] and residues 116-122 
in aPKC-6 (N.T. Goode and P.J. Parker, unpublished). cPKC-c~ and 
nPKC-e were in vector pMT2 under the control of an SV40 promoter 
[21] and aPKC-6 was in vector pCO2 (provided by Dr. Steve 
Goodbown, Imperial Cancer Research Fund Laboratories) under the 
control of a CMV promoter. 
The ANF-LUX reporter vector, pANF(-638)Ld5’ [22], the 2 x AP-I/ 
LUX construct TRE2PRL(-36) [23], the corresponding control plas- 
mids pSVOALd5’ and PRL(-36), and an expression vector (pON249) 
in which the /?-Gal gene is under the control of the human CMV 
promoter [24] were generously provided by Drs. Ken Chien, Geoff 
Rosenfeld and Joan Heller Brown (University of California, San 
Diego). 
Plasmids were purified by polyethylene glycol precipitation following 
alkaline lysis of the bacterial host [25] and experiments used at least two 
different preparations of each plasmid. 
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2.2. Transfections and assays 
Ventricular cardiomyocytes were isolated from the hearts of 1- to 
2-day-old Sprague-Dawley rats by the method of Iwaki et al. [26] with 
minor modifications. After 24 h in culture, cardiomyocytes (lo6 cells/60 
mm dish) were transfected. A few hours prior to transfection the me- 
dium on the cells was changed to 4% horse serum in 4 ml of mainte- 
nance medium (DMEM/medium 199 (4: 1) containing 100 units/ml of 
both penicillin and streptomycin). Plasmids were diluted in 0.25 M 
CaCl, (500 ~1) and an equal volume of 50 mM N,N-bis(Zhy- 
droxyethyl)-2-aminoethanesulphonic ac d(pH 6.9), 280 mM NaCI, 1.5 
mM Na,HPO, was added. After a 20 min incubation to allow precipi- 
tate formation, 950 ~1 of suspension was added to the cells which were 
then incubated overnight. Each transfection used 15 pg of reporter 
plasmid, 4 pg of pON249 and 10 pg of PKC expression plasmid. The 
next day, the cells were washed once in 10% horse serum in maintenance 
medium and twice in maintenance medium. After incubation in mainte- 
nance medium for 48 h, cells were washed 3 x in ice-cold PBS and 
extracted in 0.1 M potassium phosphate (pH7.9), 0.5% (v/v) Triton 
X-100, 1 mM dithiothreitol by incubation on ice for 15 min. 
LUX was assayed by the addition of extract (20 ~1) to 100 mM 
Tricine @H 7.8), 10 mM MgSO,, 2 mM EDTA, 75 mM luciferin, 5.5 
mM ATP (0.5 ml). Light emitted was quantitated in an LKB 1219 
RackBeta liquid scintillation counter with the photomultipliers et out 
of coincidence. B-Gal was assayed by addition bf extract (iO0 ~1) to 0.1 
M sodium uhosuhate toH7.3). 1.5 mM M&I,. 75 mM 2-mercaotoetha- ~. I. I _, 
nol, 2 mg/ml o:nitrophenyl-/?-o-galactopyranoside (200 ~1) and incu- 
bated at 37’C for l-3 h. The reaction was terminated by the addition 
of 0.5 ml of 0.5 M Na,CO, and A4,0 measured. 
Results are mean f S.E.M. for 5-6 separate preparations (unless 
stated otherwise) of cardiomyocytes. 
3. Results 
cPKC-a(A,, + E) or cPKC-a(&SS) stimulated expression 
of ANF-LUX in cardiomyocytes by 2- to 3-fold compared with 
cPKC-a(wt) or empty vector (Fig. 1A). nPKC-&(A,,,+E) and 
nPKC-.$&SS) stimulated ANF-LUX by 2- to 3-fold com- 
pared with empty vector (Fig. 1A). nPKC+(wt) also stimulated 
ANF-LUX expression significantly although stimulation was 
less than with the constitutively active constructs (Fig. 1A). 
Results were unchanged when normalised for B-Gal activity 
(Fig. 1A). aPKC-[(A,,,+E) and aPKC-&lylSS) caused the 
most marked stimulation of ANF-LUX (5- to 6-fold compared 
with empty vector) and again aPKC-[(wt) stimulated ANF- 
LUX though less than the constitutively active constructs (Fig. 
1A). Stimulation by wild type constructs is presumably caused 
by over-expression of PKCs with low activity although more 
complex explanations are possible (e.g. their presence removes 
a repressor from the ANF promoter). 
When aPKC-c-stimulated ANF-LUX activity was normal- 
ised for #?-Gal activity, no stimulation by aPKC-&wt), aPKC- 
c(A,,9-+E) or aPKC-&lvSS) was detectable (Fig. 1B). This 
anomaly arose from inhibition of /?-Gal expression from 
pON249 by the empty pCO2 vector which did not occur with 
the pC02-aPKC-c constructs. The pCO2 vector and pON249 
both use a CMV promoter and promoter competition is likely 
to have been a problem. There was no detectable LUX activity 
in cells co-transfected with PKC-expression plasmids and the 
promoterless backbone LUX vector pSVOALJ5’ (results not 
shown). 
The sensitivity of TREIAP-1 sites to activation by cPKC-a, 
nPKC-& and aPKC-6 was examined in cardiomyocytes using 
the TRE2PRL(-36) reporter plasmid [23]. LUX activity was 
stimulated lo- to 1Zfold by cPKC-a(&SS) or nPKC-@rySS) 
compared with vector alone whereas aPKC-&lylSS) stimu- 
lated activity about 4-fold (Fig. 2A). For nPKC-&, constructs 
containing nPKC-&(wt) or nPKC+(A,,,+E) did not signifi- 
cantly stimulate LUX activity (Fig. 2A). Analogous constructs 
for aPKC-a and nPKC-% were not tested. Normalisation for 
B-Gal activity did not alter interpretation of these results, with 
the exception of aPKC-[ where the stimulation was masked 
because of the inhibition of B-Gal expression by the empty 
pCO2 vector. There was no measurable LUX activity under 
any conditions when TRE2PRL(-36) was replaced by PRL(-36) 
(results not shown). 
We compared the magnitude of the stimulation of ANF- 
LUX or TRE2PRL(-36) expression by PKC expression con- 
structs with stimulation by 1 PM TPA. TPA stimulated ANF- 
LUX expression by 33.0 + 14.6-fold and ANF-LUX@Gal by 
14.3 f 6.9-fold in cardiomyocytes transfected with ANF- 
LUX + pON249 (n = 4). Similarly, TPA stimulated 
TRE2PRL(-36) expression by 43.3 + 4.3-fold and ANF-LUX/ 
/?-Gal by 13.6 + 1.3-fold in cells transfected with TRE2PRL- 
(-36) and pON249 (n = 3). 
4. Discussion 
The 638 bp of the ANF gene regulatory sequence 5’ to the 
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Fig. 1. Stimulation of ANF promoter activity in neonatal ventricular 
myocytes by expression of constitutively active isoforms of PKC. 
Transfection and extraction of cells was carried out as described in the 
Experimental section. Data are expressed relative to transfection with 
empty vector. (A) LUX activity. (B) LUX activity normalised top-Gal. 
Statistical significance: *P<O.O5; **P<O.O2 by a 2-tailed Student’s 
t-test for paired data. 
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Fig. 2. Stimulation of TRE/AP-l-regulated promoter activity in neona- 
tal ventricular myocytes by expression ofconstitutively active isoforms 
of PKC. Transfection and extraction of cells was carried out as de- 
scribed in section 2. Data are expressed relative to transfection with 
empty vector. (A) LUX activity. (B) LUX activity normalised top-Gal. 
Statistical significance: *P<O.O5; **P<O.O2 by a 2-tailed Student’s 
t-test for paired data. 
transcriptional start site confer inducibility of ANF gene ex- 
pression in response to the hypertrophic agonist phenylephrine 
in ventricular cardiomyocytes [22]. Ventricular re-expression of 
ANF is a marker for the hypertrophic response that is seen in 
vivo and in cultured cardiomyocytes (reviewed in [l]). Within 
the 638 bp sequence are CRE (CAMP response element), TRE/ 
AP- 1 (c-foslc-jun heterodimer binding), AP-2, Egr- 1 and CArG 
consensus sequences [22]. 
The most direct evidence of an involvement of PKC in the 
regulation of ANF gene transcription is the demonstration that 
transfection of cardiomyocytes with constitutively-active 
cPKC-a or cPKC-b stimulated ANF-LUX expression by 2- to 
3-fold relative to B-Gal [3]. Other marker genes (MLC-2, 
/3-MHC) are up-regulated by these PKC constructs [3,13]. 
This response is presumably mediated at least in part through 
TRE/AP-1 sites [3]. 
There are two difficulties with these studies. First, cPKC-a 
and cPKC-b were rendered constitutively active by deletion of 
more than half of N-terminal regulatory domain (residues l- 
253 from cPKC-a and 6159 from cPKC-/?). The consequences 
of these deletions in terms of the properties of the PKCs ex- 
pressed have not been fully assessed. However the regulatory 
domain contains regions that play a role in substrate selection 
[27], effector binding [20] and subcellular localisation [28] in 
addition to containing the @S (reviewed in [14]). Secondly, of 
cPKC-a, cPKC-&I/$,, cPKC-y, nPKC-6, nPKC-& and aPKC-c, 
the isoforms most readily detectable in cultured neonatal cardi- 
omyocytes by immunoblotting are nPKC-6, nPKC-& and 
aPKC-[ [5,6,17]. cPKC-a is more difficult to detect, and cPKC- 
/&/BII and cPKC-y are not detectable [5,6,17]. Furthermore, 
when cultured neonatal cardiomyocytes are exposed to hy- 
pertrophic agonists (endothelin-1, phenylephrine), nPKC-& is 
the isoform most readily activated (translocated) [7]. 
We used expression vectors encoding PKC isoforms ren- 
dered constitutively active by single amino acid mutations or 
small deletions within the @S. The PKCs expressed are consti- 
tutively-active [18-201 but retain regulatory sequences associ- 
ated with substrate selection [27] and determination of subcellu- 
lar localisation [28]. In addition, the range of PKC subfamilies 
studied has extended to include an nPKC and an aPKC. ANF- 
and TRE-regulated-promoter activities were increased by 
cPKC-a, nPKC+ and aPKC-6 (Figs. 1 and 2). This implies that 
a TREIAP-1 site may be at least partly responsible for the 
stimulation of ANF promoter activity. No significant differ- 
ence between isoforms in terms of their ability to cause transac- 
tivation of ANF and TRE-regulated promoter activity was 
detected except hat aPKC-6 may be more efficient than cPKC- 
a or nPKC-& at transactivating the ANF promoter (Fig. 1A) 
but less efficient than cPKC-a or nPKC-.z at transactivating at 
TRE sites (Fig. 2A). This pluripotency implies that any specific- 
ity in terms of mediation of the hypertrophic response by PKC 
isoforms would reside elsewhere in the signalling pathway. 
Thus, we have recently shown that there may be differences 
between isoforms in terms of their ability to be activated by 
hypertrophic agonists [7]. From the teleological standpoint, the 
demonstration of the sensitivity of the ANF promoter to 
nPKC-& is important because this isoform is the most readily 
detectable in adult rat heart [4] which is known to re-express 
ANF on hypertrophy (reviewed in [I]. 
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